Physician preference for antiepileptic drug concentration testing

Pediatric Neurology

Volumn 30, Issue 1, 2004, Pages 29-32

  Baumann, Robert J ^a,d   Ryan, Melody ^a,b   Yelowitz, Aaron ^c  

^a UNIVERSITY OF KENTUCKY   (United States)

^b University of Kentucky   (United States)

^c UNIVERSITY OF KENTUCKY   (United States)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT;

ARTICLE; ATTITUDE; CHILD; CONTROLLED STUDY; DRUG MONITORING; DRUG PREFERENCE; DRUG SALIVA LEVEL; EPILEPSY; EXPERIMENTAL TEST; HOME MONITORING; HUMAN; METABOLISM; METHODOLOGY; PAIN; PHYSICIAN; PRIORITY JOURNAL; QUESTIONNAIRE; SALIVA; SEIZURE; SIDE EFFECT; TECHNIQUE; UNITED STATES;

EID: 0347130957     PISSN: 08878994     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0887-8994(03)00410-7     Document Type: Article

References (24)

1. Hauser W.A., Hesdorffer D.C. Remission, intractability, morality, and comorbidity of seizures. Wyllie E. The treatment of epilepsy Principles and practice . 2001;139-145 Lippincott Williams & Wilkins, Philadelphia.
2. Leppik I.E. Laboratory tests. Engel J. Jr, Pedley T.A. Epilepsy A comprehensive textbook . 1998;811-817 Lippincott-Raven, Philadelphia, New York.
3. Birnbaum A.K., Kriel R.L., Cloyd J.C. Pharmacokinetics in infancy, childhood, and adolescence. Wyllie E. The treatment of epilepsy Principles and practice . 2001;741-757 Lippincott Williams & Wilkins, Philadelphia.
4. Kriel R.L., Birnbaum A.K., Cloyd J.C. Antiepileptic drug therapy in children. Swaiman K.F., Ashwal S. Pediatric neurology Principles and practice . 1999;692-718 Mosby, St. Louis.
5. Menkes J.H., Sankar R. Paroxysmal disorders. Menkes J.H., Sarnat H.B. Child neurology. 2002;919-1026 Lippincott Williams & Wilkins, Philadelphia.
6. Pichini S., Altieri I., Zuccaro P., Pacifici R. Drug monitoring in nonconventional biological fluids and matrices. Clin Pharmacokinet. 30:1996;211-228.
7. Rylance G.W., Moreland T.A. Saliva carbamazepine and phenytoin level monitoring. Arch Dis Child. 56:1981;637-640.
8. Bailey B., Klein J., Koren G. Noninvasive methods for drug measurement in pediatrics. Pediatr Clin North Am. 44:1997;15-26.
9. Child Neurology Society. Child Neurology Society Directory 2000. St. Paul, Minnesota: Child Neurology Society, 2000.
10. U. S. Census Bureau. Census regions and divisions of the United States. http://www.census.gov/geo/www/us_regdiv.pdf. 2002.
11. Tal A., Aviram M., Gorodischer R. Variations in theophylline concentrations detected by 24-hour saliva concentration profiles in ambulatory children with asthma. J Allergy Clin Immunol. 86:1990;238-243.
12. Rosenthal E., Hoffer E., Ben Aryeh H., Badarni S., Benderly A., Hemli Y. Use of saliva in home monitoring of carbamazepine levels. Epilepsia. 36:1995;72-74.
13. Stanaway L., Lambie D.G., Johnson R.H. Non-compliance with anticonvulsant therapy as a cause of seizures. N Z Med J. 98:1985;150-152.
14. Berndt E.R. The U.S. pharmaceutical industry Why major growth in times of cost containment? Health Aff (Millwood). 20:2001;100-114.
15. Miles M.V., Tennison M.B., Greenwood R.S., et al. Evaluation of the Ames Seralyzer for the determination of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 12:1990;501-510.
16. Miles M.V., Tennison M.B., Greenwood R.S. Intraindividual variability of carbamazepine, phenobarbital, and phenytoin concentrations in saliva. Ther Drug Monit. 13:1991;166-171.
17. Trnavska Z, Krejcova H, Tkaczykovam, Salcmanova Z, Elis J. Pharmacokinetics of lamotrigine (Lamictal) in plasma and saliva. Eur J Drug Metab Pharmacokinet 1991;3(Spec No 3):211-5.
18. Grim S.A., Ryan M., Miles M.V., et al. Correlation of levetiracetam concentrations between serum and saliva. Ther Drug Monit. 25:2003;61-66.
19. Miles MV, Tang P, Glauser TA, et al. Topiramate concentrations in saliva: An alternative to serum monitoring. Pediatr Neurol 2003;29:143-7.
20. Leppik I.E., Jacobs M.P., Loewenson R.B. Detection of adverse events by routine laboratory testing. [letter] Epilepsia. 31:1990;640.
21. Wyllie E., Wyllie R. Routine laboratory monitoring for serious adverse effects of antiepileptic medications The controversy . Epilepsia. 32:(Suppl. 5):1991;S74-S79.
22. Gorodischer R., Burtin P., Verjee Z., Hwang P., Koren G. Is saliva suitable for therapeutic monitoring of anticonvulsants in children An evaluation in the routine clinical setting . Ther Drug Monit. 19:1997;637-642.
23. Dickinson R.G., Hooper W.D., King A.R., Eadie M.J. Fallacious results from measuring salivary carbamazepine concentrations. Ther Drug Monit. 7:1985;41-45.
24. Baumann R.J., Wilson J.F., Wiese H.J. Kentuckians' attitudes toward children with epilepsy. Epilepsia. 36:1995;1003-1008.